focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,172.00
Bid: 12,168.00
Ask: 12,170.00
Change: -74.00 (-0.60%)
Spread: 2.00 (0.016%)
Open: 12,240.00
High: 12,306.00
Low: 12,132.00
Prev. Close: 12,246.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

FOREX-Dollar holds firm in cautious trading before Fed meets

Tue, 16th Mar 2021 04:29

* Yen hovers at nine-month lows, euro flat
* Focus on Fed comments about higher bond yields
* Sterling dips ahead of BoE meeting on Thursday
* Graphic: World FX rates https://tmsnrt.rs/2RBWI5E

(Adds analyst comments; updates prices)
By Kevin Buckland and Sagarika Jaisinghani
TOKYO, March 16 (Reuters) - The U.S. dollar clung to small
gains on Tuesday as caution reigned in currency markets ahead of
major central bank meetings, beginning with a two-day Federal
Reserve gathering due to start later in the global day.
The greenback hovered just off its highest since June versus
the yen and cemented a position around $1.19 per euro
in muted trading.
The firmer tone for the dollar came despite a retreat in
U.S. benchmark yields from the highest levels in more than a
year ahead of the Fed meeting.
Expectations are running low for monetary policymakers to
shift from their accommodative stance despite forecasts of rapid
economic growth in the wake of an accelerating COVID-19 vaccine
roll-out and a $1.9 trillion pandemic relief package.

Investors will pore over whatever the Fed has to say about
the run-up in yields, which have risen on bets that economic
growth and inflation could prompt a faster-than-expected
normalisation of monetary policy.
"It's a very pivotal meeting from that perspective," said
Mayank Mishra, an FX strategist at Standard Chartered Bank in
Singapore.
"The other thing that is being awaited is any decision on
the supplemental leverage ratio (SLR) exemption. We don't expect
any explicit push back on back-end yields, but an extension of
the SLR can offer some relief to the market."
The SLR exemption, a regulatory break that allows big banks
to exclude reserve deposits and Treasuries from capital ratios,
is due to expire on March 31.
The dollar was little changed at 109.170 yen after rising to
a nine-month high of 109.365 on Monday. The Bank of Japan begins
a two-day policy meeting on Thursday, along with an extensive
policy review.
The euro was largely flat at $1.19330, languishing below
$1.20 since March 5. Europe's vaccine roll-out has been hampered
by the suspension of AstraZeneca shots in Germany,
France and other nations amid concerns about possible serious
side effects.
Sterling fell about 0.2% to $1.3871 ahead of a Bank
of England meeting on Thursday, where the central bank is
expected to keep its benchmark interest rate at its historic low
of 0.1% and its bond-buying programme unchanged.
The dollar's index against six major currencies was flat at
91.798 after rising nearly 0.2% on Monday.
The Australian dollar, viewed widely as a liquid
proxy for risk appetite, and the New Zealand dollar were
little changed against the U.S. dollar. The commodity-linked
currencies are on course to post their fourth straight quarterly
gain as commodity prices rebound on bets of economic growth.
Bitcoin, meanwhile, slipped to $54,198.64 following its jump
to a record $61,781.83 on Saturday.

========================================================
Currency bid prices at 0400 GMT
Description RIC Last U.S. Close Pct Change YTD Pct High Bid Low Bid
Previous Change
Session
Euro/Dollar $1.1934 $1.1929 +0.04% -2.32% +1.1937 +1.1923
Dollar/Yen 109.1550 109.1200 +0.06% +5.71% +109.2400 +109.1900
Euro/Yen 130.26 130.16 +0.08% +2.63% +130.3900 +130.1400
Dollar/Swiss 0.9266 0.9275 -0.10% +4.74% +0.9279 +0.9266
Sterling/Dollar 1.3869 1.3900 -0.21% +1.53% +1.3903 +1.3867
Dollar/Canadian 1.2478 1.2473 +0.05% -2.00% +1.2487 +1.2468
Aussie/Dollar 0.7752 0.7756 -0.05% +0.77% +0.7755 +0.7742
NZ 0.7195 0.7200 +0.00% +0.26% +0.7205 +0.7195
Dollar/Dollar


All spots
Tokyo spots
Europe spots
Volatilities
Tokyo Forex market info from BOJ



(Reporting by Kevin Buckland in Tokyo and Sagarika Jaisinghani
in Bengaluru; Editing by Christopher Cushing & Simon
Cameron-Moore)

More News
12 May 2024 13:25

Pfizer and AstraZeneca announce new investments of nearly $1 billion in France

PARIS, May 12 (Reuters) - Leading healthcare companies Pfizer and AstraZeneca announced on Sunday new investments in France worth a total of nearly $1 billion, ahead of the start of this year's annual 'Choose France' business summit.

Read more
8 May 2024 19:10

Sector movers: Aerospace and Defence, Pharma pace gains

(Sharecast News) - London's main stock market gauges continued to push higher in the middle of the week, even as investors waited on the Bank of England's policy announcement on the following day.

Read more
8 May 2024 17:46

FTSE 100 hits record high, pound slips ahead of BoE verdict

FTSE 100 up 0.5%, FTSE 250 adds 0.4%

*

Read more
8 May 2024 16:36

London close: Stocks rise further ahead of BoE decision

(Sharecast News) - London's stock markets closed with gains on Wednesday, bolstered by a dip in the value of the pound against both the dollar and the euro.

Read more
8 May 2024 09:44

AstraZeneca says withdraws Covid vaccine "for commercial reasons"

(Alliance News) - Drugmaker AstraZeneca PLC said Wednesday that it has withdrawn its Covid vaccine Vaxzevria, one of the first produced in the pandemic, citing "commercial reasons" and a surplus of updated jabs.

Read more
8 May 2024 09:39

LONDON BROKER RATINGS: UBS raises Centrica to 'buy' from 'neutral

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
7 May 2024 15:54

Berenberg hikes target price on Astrazeneca

(Sharecast News) - Analysts at Berenberg hiked their target price on drugmaker Astrazeneca from 1,200.0p to 1,300.0p on Tuesday, citing the group was "instilling confidence in the revenues of tomorrow".

Read more
7 May 2024 09:51

LONDON BROKER RATINGS: AstraZeneca target raised; Antofagasta lowered

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday:

Read more
6 May 2024 07:46

AstraZeneca completes collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Monday said it has completed an equity investment in clinical-stage biotechnology company Cellectis, first announced in November.

Read more
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.